
    
      Subjects were previously vaccinated at 2 to 10 years of age with GSK134612 or with
      MenjugateÂ®. The persistence phase starts 32 months after the primary vaccination and blood
      samples will be taken at 32, 44, 56 and 68 months after primary vaccination. All subjects
      will receive a booster dose of GSK134612 at 68 months after primary vaccination and a blood
      sample will be taken 1 month after administration of the booster dose.
    
  